Percutaneous Intervention Versus Surgery in the Treatment of Common Femoral Artery Lesions

Inclusion Criteria: 1. Subject must be between 21 and 85 years old; 2. Female of childbearing potential must have a negative pregnancy test within 10 days prior to index procedure and utilize reliable birth control until completion of the 12-month angiographic evaluation; 3. Clinical diagnosis of symptomatic peripheral artery disease defined by Rutherford 2, 3, or 4; 4. Common femoral artery (CFA) stenosis (including CFA bifurcation) \>70% (visual estimate) or occlusion; Additional non-target lesion(s) in remaining non-target vessel(s), except ipsilateral iliac arteries, can be treated at the physician´s discretion; 5. At least one vessel outflow (infrapopliteal arteries) to the foot (without stenosis \>50%). 6. Endovascular Procedure: successful target lesion crossing of the guidewire (guidewire located intraluminally); 7. Non-target lesion interventions (TASC A and B) to restore adequate blood flow, in the same index procedure are allowed. This intervention must be prior to the treatment of the study lesion and successful; 8. Willing to comply with the specified follow-up evaluation; 9. Written informed consent prior to any study procedures. Exclusion Criteria: 1. Ipsilateral significant (\>50%) stenosis of the iliac arteries. 2. Significant (\>50%) stenosis of all infrapopliteal arteries, no patent artery to the foot. 3. Angiographic evidence of thrombus within target vessel; 4. Thrombolysis within 72 hours prior to the index procedure; 5. In-Stent restenosis or restenosis of the native common femoral artery. 6. Aneurysm in the abdominal aorta or iliac arteries; 7. Concomitant hepatic insufficiency, thrombophlebitis, deep venous thrombus, coagulation disorder or receiving immunosuppressant therapy; 8. Recent MI or stroke \< 30 days prior to the index procedure; 9. Life expectancy less than 24 months; 10. Known or suspected active infection at the time of the index procedure; 11. Known or suspected allergies or contraindications to aspirin, clopidogrel bisulfate (Plavix) and ticlopidine (Ticlid), heparin, or contrast agent; 12. Any significant medical condition which, in the investigator´s opinion, may interfere with the subject´s optimal participation in the study; 13. The subject is currently participating in another investigational drug or device study that has not completed the primary endpoint or that clinically interferes with the endpoints of this study.